<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02785822</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-FOS-2016-01</org_study_id>
    <nct_id>NCT02785822</nct_id>
  </id_info>
  <brief_title>Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle.</brief_title>
  <official_title>Randomized, Single Blind, Prospective Clinical Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Programa de Reproducción Asistida F. Puigvert - HSCSP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary occurs in 15-20% of the population will be submitted to TRA. Whether it is&#xD;
      associated with other signs or symptoms (polycystic ovarian syndrome) as if presented in&#xD;
      isolation, its therapeutic management has special connotations sometimes favoring the low&#xD;
      response although the standard is the tendency to hyperresponsiveness.&#xD;
&#xD;
      Although there are studies comparing the combination of FSH and LH and FSH in controlled&#xD;
      hyperstimulation of these patients, there are no previous prospective randomized studies&#xD;
      comparing administration of urinary FSH (hFSH-HP) with a combination of FSH and HCG (HMG HP).&#xD;
&#xD;
      Therefore the aim of this study is to prove that both drugs are comparable in the treatment&#xD;
      of these patients. The test substances are marketed in Spain (Fostipur and Meriofert,&#xD;
      respectively) with an indication for use in these patients. In this study both medicines will&#xD;
      be administered in a randomized way under the usual conditions in which it is used in routine&#xD;
      clinical practice to compare the quantity of mature oocytes respect to the total oocytes&#xD;
      obtained, as a primary outcome measure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties in recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">February 23, 2017</start_date>
  <completion_date type="Actual">May 9, 2018</completion_date>
  <primary_completion_date type="Actual">May 9, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantity of mature oocytes respect to the total oocytes</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Fostipur</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Meriofert</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hMG-HP</intervention_name>
    <description>Ovarian stimulation with hMG-HP (150 IU / day)</description>
    <arm_group_label>Meriofert</arm_group_label>
    <other_name>Meriofert</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hFSH-HP</intervention_name>
    <description>Ovarian stimulation with hFSH-HP (150 IU / day)</description>
    <arm_group_label>Fostipur</arm_group_label>
    <other_name>Fostipur</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female age between 18 and 38 years (inclusive)&#xD;
&#xD;
          -  Women with a BMI under 30 kg / m2&#xD;
&#xD;
          -  Diagnosis of polycystic ovary syndrome (according to criteria of Rotterdam)&#xD;
&#xD;
          -  Women who want pregnancy&#xD;
&#xD;
          -  Basal basal FSH levels under or equal 10 IU / l&#xD;
&#xD;
          -  Infertility justify treatment with in vitro fertilization / intracytoplasmic sperm&#xD;
             injection&#xD;
&#xD;
          -  To be included in a protocol with GnRH antagonist&#xD;
&#xD;
          -  Presence of both ovaries and uterus able to support embryo implantation and pregnancy&#xD;
&#xD;
          -  Absence of pregnancy before starting ovarian stimulation&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe male factor not allowing an in vitro fertilization / intracytoplasmic sperm&#xD;
             injection with ejaculated sample&#xD;
&#xD;
          -  Patients with low ovarian reserve&#xD;
&#xD;
          -  Important endocrine-metabolic systemic diseases affecting pituitary, thyroid,&#xD;
             adrenals, pancreas, liver or kidney&#xD;
&#xD;
          -  HIV seropositivity&#xD;
&#xD;
          -  To have frozen embryos from previous cycles of assisted reproduction&#xD;
&#xD;
          -  Undiagnosed vaginal haemorrhage&#xD;
&#xD;
          -  Poor response in previous cycles of in vitro fertilization with standard stimulation&#xD;
             protocols&#xD;
&#xD;
          -  Pregnancy, lactation or contraindication to get pregnant&#xD;
&#xD;
          -  Malformations of the sexual organs incompatible with pregnancy&#xD;
&#xD;
          -  History of allergy to gonadotrophin preparations or its excipients&#xD;
&#xD;
          -  Alcohol, drugs or psychotropic addiction&#xD;
&#xD;
          -  Concurrent participation in another study&#xD;
&#xD;
          -  Previous history of severe hyperstimulation syndrome&#xD;
&#xD;
          -  Concomitant medication that may interfere with the study medication: different&#xD;
             hormonal treatments used in the study, other thyroid hormones, antipsychotics,&#xD;
             anxiolytics, hypnotics, sedatives, chronic treatment with inhibitors of prostaglandin&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan J Espinos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundació Puigvert</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2016</study_first_posted>
  <last_update_submitted>February 21, 2019</last_update_submitted>
  <last_update_submitted_qc>February 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Reproductive Techniques, Assisted</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

